MedTrace Logo

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

NCT00874926 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 405

Last updated 2014-01-29

No results posted yet for this study

Summary

The aim of this international prospective, non-interventional post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer in treatment of patients with haemophilia A under daily-life treatment conditions.

Conditions

Interventions

BIOLOGICAL

Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Haemophilia A patients

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2012-11-30
Completion
2013-04-30

Countries

  • Bahrain
  • Bosnia and Herzegovina
  • Croatia
  • Germany
  • Israel
  • Kazakhstan
  • Kuwait
  • Libya
  • Morocco
  • Oman
  • Qatar
  • Romania
  • Russia
  • Saudi Arabia
  • Slovenia
  • Tunisia
  • United Arab Emirates

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00874926 on ClinicalTrials.gov